Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Study to Evaluate Safety and Efficacy of Elagolix Alone or Elagolix With Hormonal Add-Back in Subjects With Endometriosis With Associated Moderate to Severe Pain

NCT03343067 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT03343067
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03343067 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Study to Evaluate Safety and Efficacy of Elagolix Alone or Elagolix With Hormonal Add-Back in Subjects With Endometriosis With Associated Moderate to Severe Pain
Lead sponsor
AbbVie
Phase
Phase 3
Overall status
Terminated
Start date
December 27, 2017
Completion date
October 23, 2018
Enrollment
11 (actual)
Sites
37

Conditions

As the registry lists them; a condition with its own page is linked.

endometriosis